immatics Appoints Peter Chambré as Chairman
News Nov 12, 2012
immatics biotechnologies GmbH has announced the appointment of Peter Chambré as Chairman of the Board with immediate effect.
Peter Chambré has had extensive senior management experience in the biopharmaceutical sector and now holds several Chairman positions in the life sciences industry.
He will replace Thomas Widmann, who has been Chairman of the Company since 2004.
Peter Chambré was CEO of Cambridge Antibody Technology (CAT), from 2002 until its acquisition by AstraZeneca in 2006.
Before joining CAT, Peter Chambré was Chief Operating Officer of Celera Genomics Group and, previously, CEO of Bespak plc, a drug delivery company.
Following these major executive roles in the sector, Peter Chambré has held several Chairman and Non-executive Director positions.
From 2008-2010, he was Chairman of ApaTech, a specialist in orthobiologic bone graft technologies, which was acquired by Baxter Inc. in March 2010, and from 2006-2012, Non-executive Director of BTG plc.
Peter Chambré currently holds Chairman and Non-executive Board roles with a number of companies.
Paul Higham, CEO of immatics, said: “I am delighted to welcome Peter as our new Chairman. We are approaching a crucial period at immatics, and Peter’s experience and track record in successfully developing biopharmaceutical companies will be invaluable, as we seek to produce a step-change in the treatment of cancer and maximize returns to our investors.”
Peter Chambré said: “immatics’ vaccines, based on the Company’s highly rational approach to cancer vaccine discovery, have already demonstrated very promising results in clinical trials. With IMA901, immatics’ lead multi-peptide based vaccine now in phase 3 development for renal cancer, and a number of other projects in clinical development, this is an extremely exciting company. On behalf of immatics, I would like to express my thanks to Thomas Widmann for his very significant contribution to the development of the Company over the past 8 years. I very much look forward to working with the Board and management, as immatics aims to improve outcomes for cancer patients and create value for all its stakeholders.”
Comments | 0 ADD COMMENT
Tempus, UPenn Team Up to Improve Leukemia Treatment
News Apr 28, 2017